Samsung Biologics and Checkpoint Therapeutics have expanded their long-term manufacturing partnership for Checkpoint's anti-programmed cell death ligand 1 (PD-L1) antibody, cosibelimab. The agreement builds on an existing agreement in 2017. Now, Samsung Biologics will provide additional commercial-scale drug substance manufacturing for Checkpoint. Samsung will begin manufacturing in 2021.

Cosibelimab is currently under clinical investigation for the treatment of metastatic cutaneous squamous cell carcinoma. Checkpoint anticipates reporting results from the trial in mid-2021.

Samsung Biologics has also entered into a new strategic partnership with GeneQuantum Healthcare in China for the joint development of an antibody drug conjugate (ADC) for the treatment of non-small cell lung carcinoma, triple-negative breast cancer, and other solid tumors. GeneQuantum has chosen Samsung Biologics as its CDMO partner for its second antibody candidate.

Samsung Biologics, BioEleven partner on cancer immunotherapy
Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat...

Samsung Biologics, Kanaph Therapeutics partner on retinal disease therapy
Samsung Biologics and Kanaph Therapeutics are partnering on the development of KNP-301, a bispecific Fc fusion protein to treat retinal diseases.

Samsung Biologics, AstraZeneca ink manufacturing deal
Samsung Biologics and AstraZeneca have signed a $330.8 million long-term supply agreement.

PharmAbcine, Samsung Biologics expand partnership
PharmAbcine and Samsung Biologics have entered into a new strategic partnership for the development and manufacturing of PMC-403, a next-generation antibody...

Samsung Biologics adds new manufacturing plant
Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and...